Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLTC | Q00610 | 10/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL25250540 | 1.00 | CLTC (0.42) | CLTCFTOMEN1POLBCCR6 | |
| Lithium Ion SCHEMBL94590 | 0.85 | CLTC (0.42) | CLTCFTOMEN1POLBCCR6 | |
| SCHEMBL16097930 | 0.83 | ALDH1A1 (0.33) | CLTC | |
| Potassium Ion SCHEMBL5415633 | 0.77 | CLTC (0.45) | CLTCFTOMEN1POLBCCR6 | |
| Potassium Ion SCHEMBL4636440 | 0.72 | CLTC (0.46) | CLTCFTOMEN1POLBCCR6 | |
| Potassium Ion SCHEMBL31670338 | 0.72 | CLTC (0.46) | CLTCFTOMEN1POLBCCR6 | |
| Lithium Ion SCHEMBL95351 | 0.69 | CLTC (0.44) | CLTCMEN1KMT2A | |
| Lithium Ion SCHEMBL29875131 | 0.69 | CLTC (0.44) | CLTCMEN1KMT2A | |
| SCHEMBL8032702 | 0.68 | ALDH1A1 (0.33) | CLTC | |
| SCHEMBL7705622 | 0.67 | ALDH1A1 (0.32) | CLTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6007 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637679-B2 | Aptamer based system to quantify anti-thrombin III in blood | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12584915-B2 | Glyphosate biosensor | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | KARLSRUHER INSTITUT FUER TECH KOERPERSCHAFT DES OEFFENTLICHEN RECHTS (DE) | 2026-02-19 | — | — | US | claimed |
| EP-4683967-A1 | LABELLED PARTICLES | COSA Group GmbH (DE) | 2026-01-28 | — | — | EP | claimed |
| EP-4676949-A2 | ANTIGEN BINDING MOLECULES AND METHODS OF USE | Kite Pharma, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-12492490-B2 | Tumor selective macropinocytosis-dependent rapidly internalizing antibodies | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | claimed |
| US-12479891-B2 | Methods of detection and removal of rhabdoviruses from cell lines | TAKEDA VACCINES, INC. (US) | 2025-11-25 | — | — | US | claimed |
| US-20250341516-A1 | COMPOSITIONS FOR USE WITH MULTIPLE FLUOROPHORES AND METHODS OF USING | BIOLEGEND INC (US) | 2025-11-06 | — | — | US | claimed |
| EP-4007767-A1 | GLYPHOSATE BIOSENSOR | The Trustees of Indiana University (US) | 2022-06-08 | — | — | EP | claimed |
| EP-2519823-B1 | COMPOSITE PROBES AND USE THEREOF IN SUPER RESOLUTION METHODS | US HEALTH (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220146519-A1 | INTEGRIN ALPHA V BETA 3 TARGETING PROBE FOR DIAGNOSING RETINOCHOROIDAL NEOVASCULAR DISEASES AND PREPARATION METHOD THEREFOR | SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) | 2022-05-12 | — | — | US | claimed |
| EP-3186331-B1 | COMPOSITE COMPRISING WELL TREATMENT AGENT AND/OR A TRACER ADHERED ONTO A CALCINED SUBSTRATE OF A METAL OXIDE COATED CORE AND A METHOD OF USING THE SAME | BAKER HUGHES HOLDINGS LLC (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| EP-3983435-A2 | ANTI-TALEN ANTIBODIES AND USES THEREOF | Allogene Therapeutics, Inc. (US) | 2022-04-20 | — | — | EP | claimed |
| WO-2022063178-A1 | FLUORESCENT BIOSENSOR FOR RAPID DETERMINATION OF L-ARGININE | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-03-31 | — | — | WO | claimed |
| US-20220098648-A1 | OLIGONUCLEOTIDE-BASED PROBES AND METHODS FOR DETECTION OF MICROBES | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2022-03-31 | — | — | US | claimed |
| US-20220088135-A1 | METHODS OF MAKING AND USING SOLUBLE MHC MOLECULES | KITE PHARMA INC (US) | 2022-03-24 | — | — | US | claimed |
| EP-3956363-A1 | ANTIBODIES AGAINST 4G7-DERIVED CHIMERIC ANTIGEN RECEPTORS | Allogene Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | claimed |